My Investing News on MSN
Bill Ackman has over $7 billion in just 3 stocks
Key Points Bill Ackman built his reputation through high-conviction bets that produced both massive wins and notable failures. Ackman’s top positions, Howard Hughes, Brookfield, and Uber, reflect long ...
Bill Ackman, the CEO of Pershing Square Capital Management, has historically invested in a very different manner than Warren ...
After a rocky year, stalwart investors of Herbalife Ltd. (NYSE:HLF) are being rewarded for their commitment to the company, with shares soaring 33% in March after a shareholder lawsuit against the ...
Investing giant Carl Icahn is still fighting his war of words against hedge fund rival Bill Ackman, but he swears it's not about personal feelings—it's about making money. Hurting Ackman's feelings in ...
Hedge fund billionaire Bill Ackman criticized Harvard University for becoming “a political advocacy organization” in a CNBC interview. Howard Hughes Holdings said Bill Ackman’s Pershing Square Capital ...
Remember a couple of months ago, when hedge fund giant Carl Icahn went nuclear on hedge fund giant Bill Ackman for short-selling Herbalife stock? Turns out the spat might've made both men millions. On ...
The Herbalife Plaza in Torrance, California, on May 1, 2016. Bloomberg photo by Patrick T. Fallon. The documentary film "Betting on Zero," which chronicles hedge fund manager Bill Ackman's attempt to ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Even though he's a billionaire, shorting shares of ...
A ‘shock pause’ by the central bank would spook an already jittery market, one analyst said, even as shares in regional lenders fall. By Andrew Ross Sorkin, Ravi Mattu, Bernhard Warner, Sarah Kessler, ...
Hedge fund manager Bill Ackman is one of more controversial figures on Wall Street. The head of the $12 billion Pershing Square Capital Management fund has gained the ire of several peers, including ...
Bill Ackman's Pershing Square L.P. hedge fund returned 25% in the first half of the year, according to an investor update, helped by the activist investor's backing of a hostile takeover bid for Botox ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results